## TITLE PAGE

**Title:** *Protective lipid-lowering genetic variants in healthy older individuals without coronary heart disease* 

Running title: Lacaze - Protective lipid-lowering variants

**Authors:** Paul Lacaze, PhD<sup>1\*</sup>, Moeen Riaz, PhD<sup>1</sup>, Robert Sebra, PhD<sup>2</sup>, Amanda J Hooper, PhD<sup>3,4</sup>, Jing Pang, PhD<sup>3</sup>, Jane Tiller, LLB, MSc GenCoun<sup>1</sup>, Galina Polekhina, PhD<sup>1</sup>, Andrew M Tonkin, PhD<sup>1</sup>, Christopher M Reid, PhD<sup>1,5</sup>, Sophia Zoungas, MD, PhD<sup>1</sup>, Anne M Murray, MD, MSc<sup>6</sup>, Stephen J Nicholls MD, PhD<sup>7</sup>, Gerald F Watts, MD, PhD<sup>4,8</sup>, Eric Schadt, PhD<sup>2</sup> & John J McNeil, MD, PhD<sup>1</sup>

# **Departments and institutions:**

<sup>1</sup> Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

<sup>2</sup> Department of Genetics and Genomic Sciences, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, USA.

<sup>3</sup> School of Medicine, Faculty of Medicine and Health Sciences, The University of Western Australia, Perth, Australia

<sup>4</sup> Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth, Western Australia, Australia.

<sup>5</sup> School of Public Health, Curtin University, Perth, WA, Australia

<sup>6</sup> Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Hennepin Healthcare, Minneapolis, MN, USA

<sup>7</sup> Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Clayton, Victoria, Australia;

<sup>8</sup> Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Australia.

# **Corresponding author:**

\*Paul Lacaze, PhD. paul.lacaze@monash.edu

Department of Epidemiology and Preventive Medicine,

School of Public Health and Preventive Medicine

Monash University, Level 5, The Alfred Centre

99 Commercial Road, Melbourne VIC 3004, Australia.

Ph. +61 3 9903 0412, Fax: +61 3 9903 0556

ORCID ID: 0000-0002-0902-6798

Manuscript word count: 4677

Subject Terms: Genetics, Aging, Coronary Artery Disease, Lipids and Cholesterol

# ABSTRACT

**Background:** Disruptive genetic variants in the *PCSK9* and *APOB* genes result in lower serum low-density lipoprotein cholesterol (LDL-C) levels and confer protection against coronary heart disease (CHD). Few studies have measured the prevalence and selective advantage of such variants among healthy older individuals without prior CHD events.

**Methods and Results:** We performed targeted sequencing of the *PCSK9* and *APOB* genes in 13,131 healthy older individuals without CHD aged 70 years or older enrolled into the ASPirin in Reducing Events in the Elderly (ASPREE) trial. We detected predicted loss-of-function (pLoF) variants in the *PCSK9* and *APOB* genes, and associated variant carrier status with blood lipid levels. We detected 22 different rare *PCSK9/APOB* candidate variants with lipid-lowering effect, carried by 104 participants (carrier rate 1 in 126). Rare variant carrier status was associated with 19.4 mg/dl (14.6%) lower LDL-C, compared with non-carriers (P=<0.001, adjusted for statin use). Statin prescriptions were less prevalent in rare variant carriers (16%) than non-carriers (35%). The *PCSK9* R46L variant (rs11591147-T) was associated with 15.5mg/dl (11.8%) lower LDL-C in heterozygotes, and 25.2 mg/dl (19.2%) lower LDL-C in homozygotes, respectively (both P=<0.001).

**Conclusions:** Lipid-lowering genetic variants are carried by healthy older individuals and contribute to CHD-free survival.

Keywords: Genetics, lipids, cholesterol, coronary heart disease, familial hypercholesterolemia

### **1 INTRODUCTION**

Genetic variants that lower serum low-density lipoprotein cholesterol (LDL-C) levels have been demonstrated to be protective against coronary heart disease (CHD) <sup>1-9</sup>. In particular, protection can be conferred by rare loss-of-function, protein-truncating variants in canonical lipidmetabolism genes, including the apolipoprotein B (*APOB*) <sup>3</sup> and proprotein convertase subtilisin kexin type 9 (*PCSK9*) <sup>3,10</sup> genes. These protective genetic variants tend to be rare in the population. In addition, LDL-C particle size and other lipoprotein-related genotypes have been associated with CHD-free longevity <sup>11</sup>.

Familial hypobetalipoproteinemia is caused by heterozygosity for APOB variants that generally 9 10 result in LDL-C concentrations that are >50% lower than normal, while PCSK9 loss-of-function variants are associated with more modest effects of 15-40% lower LDL-C<sup>12</sup>. Discovery and 11 12 understanding of rare protective variants in these genes, particularly PCSK9, has informed the successful development of several lipid-lowering therapies <sup>13</sup>. However, most cholesterol-13 lowering variants, to date, have been identified from case-control or population-based studies <sup>1-9</sup>. 14 Healthy older populations without CHD represent an under-studied resource for the discovery 15 and understanding of protective lipid-modifying genetic variants that may reduce CHD risk. 16

With this rationale, we sequenced 13,131 healthy older individuals without CHD enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial <sup>14</sup>, with average age 75 years. Among this healthy older CHD-free population, we measured the prevalence of rare cholesterol-lowering variants in canonical lipid metabolism genes *PCSK9* and *APOB*, and associated variant carrier status with serum LDL-C and total cholesterol (TC) levels.

#### 22 **METHODS**

#### 23 Study population

Participants were enrolled in the ASPREE study, a randomized, placebo-controlled trial of 24 daily low-dose aspirin <sup>15-17</sup>. The ASPREE study design <sup>18,19</sup>, recruitment <sup>20</sup>, and baseline 25 characteristics <sup>14</sup> have been published previously. Participants had no previous diagnosis of 26 atherosclerotic or atherothrombotic cardiovascular disease, including myocardial infarction; 27 28 heart failure; angina; pectoris; stroke, or transient ischemic attack; or diagnosis of atrial fibrillation or high blood pressure <sup>21</sup>. Diagnosis of dementia or other serious illness likely to 29 cause death within 5 years were also exclusion criteria. Genetic analysis was conducted on 30 13,131 samples provided by Australian ASPREE participants aged 70 years or older at 31 enrolment <sup>22</sup>. Ethics approval for genetic analysis was obtained from the Alfred Hospital 32 Human Research Ethics Committee. 33

### 34 DNA sequencing and variant analysis

A targeted sequencing panel was designed containing the PCSK9 and APOB genes <sup>22</sup>. 35 Following standard protocols, DNA was extracted and sequenced using the Thermo Fisher 36 Scientific S5TM XL system to average 200X depth, with sequences aligned to the human 37 genome reference 37. We identified candidate cholesterol-lowering variants from sequence 38 39 data using two methods: 1) prediction of rare candidate loss-of-function, protein-truncating PCSK9 and APOB variants using the Loss-Of-Function Transcript Effect Estimator (LoFTEE) 40 tool, high-confidence filter, a plugin of Ensemble Variant Effect Predictor (VEP) <sup>23</sup>; and 2) 41 assessment of candidate variants associated with hypercholesterolaemia 42 or hypobetalipoproteinaemia identified from published functional and population studies <sup>3,10,24</sup> 43 (for list of variants meeting the inclusion criteria, see Supplementary Materials). We also 44 examined the effect of the PCSK9 R46L variant with known lipid-lowering effect (rs11591147-45 T) <sup>25</sup>. Variants were curated manually by two or more laboratory scientists following 46

ACMG/AMP Standards <sup>26</sup> and variant classification was agnostic to lipid effects. A random
selection of 10% of variants detected were validated using Sanger sequencing with 100%
concordance.

#### 50 Association of variant carrier status with blood lipid levels

We sought to determine whether PCSK9/APOB rare variant carriers in ASPREE were associated 51 with lower serum cholesterol levels at time of enrolment, versus age- and gender-matched non-52 carriers. To do this, we compared serum LDL-C and total cholesterol (TC) levels between 53 variant carriers and N=9,540 age- and gender-matched non-carrier ASPREE controls who did 54 55 not carry any PCSK9 or APOB variants that met our inclusion criteria. Baseline LDL-C and TC levels were measured in routine blood samples provided by ASPREE participants at enrolment, 56 57 analysed at commercial pathology laboratories. We tested association of variant carrier status with serum LDL-C and TC levels using multivariable linear regression, adjusting for age, 58 59 gender, diabetes, hypertension, smoking status, alcohol use, and body mass index. We first tested association using raw unadjusted LDL-C and TC levels (not accounting for statin use), then 60 separately using statin-adjusted levels, dividing by LDL-C and TC levels by 0.7 and 0.8 61 respectively for those using statin medication to estimate untreated levels, as done previously<sup>3</sup>. 62 63 We identified statin users based on concomitant medication data collected by ASPREE (Anatomical Therapeutic Chemical [ATC] code = C10, lipid modifying agents). 64

6

### 65 **RESULTS**

Characteristics of the 13,131 sequenced participants are shown in Table 1. The median age at
enrolment was 75 years; with 54% of participants female; 28% obese; and 4% current smokers.
Participants had no previous diagnosis of cardiovascular disease or dementia <sup>14</sup>. Most
participants were of European ancestry (99% self-reported as white/Caucasian).

70 Among this population, we detected a total of 104 ASPREE participants carrying rare candidate 71 loss-of-function (LoF) variants that met our inclusion criteria (MAF<0.01). This corresponded to a carrier rate of 1 in 126 participants. We detected a total of 22 different rare variants, ranging in 72 frequency between MAF=0.00335 (detected in 44 ASPREE participants) to MAF=0.00008 73 74 (singletons detected in only one ASPREE participant) (Table 2). We found six putatively novel rare APOB variants that, at the time of our analysis, were not found in the gnomAD or dbSNP 75 76 databases, and were not previously reported in the literature. Each of these rare APOB variants 77 were detected as singletons in the ASPREE cohort (MAF=0.0008) and met our criteria for loss-78 of-function (Table 2).

Based on raw LDL-C and TC levels uncorrected for statin use, rare variant heterozygous carrier
status in ASPREE (N=104 participants) was associated with 11.6 mg/dl (9.7%) lower serum
LDL-C (P<0.001) and 7.8 mg/dl (3.9%) lower serum TC (P<0.001), versus non-carriers,</li>
adjusted for age, gender, diabetes, hypertension, smoking status, alcohol use, and BMI (Table 3).

After adjusting for statin use (dividing LDL-C and TC levels by 0.7 and 0.8 respectively for those taking statin medication), rare variant heterozygous carrier status was associated with 19.4 mg/dl (14.6%) lower adjusted serum LDL-C (P<0.001) and 16.4mg/dl (7.5%) lower adjusted serum TC (P<0.001), versus non-carriers. The prevalence of lipid-lowering statin prescriptions among rare variant carriers was 16% (N=17/104), less than half that observed in non-carriers (35%, N=3324/9540).

89 The estimated median untreated LDL-C level in non-carriers was 131.5 mg/dl (110.4 to	0 154./	).
---	---------	----

- 90 compared with 112.1 mg/dl (92.8 to 139.2) in rare PCSK9/APOB variant carriers. At the per-
- 91 gene level, rare variant carrier status for PCSK9 and APOB variants separately was also
- associated with significantly lower LDL-C levels for both genes (P<0.001) (Figure 1).
- 93 For the more common PCSK9 R46L variant (rs11591147-T, ASPREE MAF=0.03541),
- heterozygous and homozygous carrier status were associated with 15.5mg/dl (11.8%) lower and
- 95 25.2 mg/dl (19.2%) lower statin-corrected LDL-C levels respectively (P=<0.001) (Table 3).

### 96 **DISCUSSION**

In this study, we identified rare PCSK9 and APOB variants that lower serum LDL-97 cholesterol levels among a population of healthy older individuals without a prior history of 98 99 CHD events. Variant carrier status was associated with significantly lower serum LDL-C and TC concentrations, using statin-corrected or uncorrected levels. The prevalence of statin 100 101 prescriptions in variant carriers were less than half that observed in non-carriers. Together, these 102 results indicate that lipid-lowering genetic variants are carried by healthy elderly individuals without CHD, and play an important role in coronary disease-free survival throughout the human 103 104 lifespan.

Consistent with other studies <sup>1-9</sup>, we observed that loss-of-function variants in *PCSK9* and *APOB* 105 106 lower serum LDL-C concentrations. However, to our knowledge, the prevalence shown in 107 ASPREE during ageing free of atherosclerotic cardiovascular disease manifestations has not previously been demonstrated. Variants analysed were found to lower serum LDL-C and TC 108 109 levels among the ASPREE population, with the difference in LDL-C concentrations between ASPREE rare variant carrier and non-carriers being ~20 mg/dl after adjusting for statin use. At 110 an average participant age of 75 years, this represents the effect of potentially a lifetime of 111 exposure to genetically-determined lower LDL-C. 112

113 Meta-analysis of statin trials suggests for a 38 mg/dl reduction in LDL-C, there is a 20-22% 114 reduction in CHD risk, in the setting of relatively short clinical trials <sup>27</sup>. Mendelian 115 randomisation studies, however, demonstrate the importance of lifetime exposure to low LDL-C, 116 suggesting that genetically-determined low LDL-C is associated with a greater magnitude of 117 CHD risk-reduction, compared with equivalent reduction through statin use <sup>28</sup>. It is therefore 118 likely that ASPREE rare variant carriers detected in this study, who have experienced a lifetime 119 of exposure to genetically lower LDL-C, have benefited substantially from lower CHD risk.

However, it is noteworthy that the rare variants detected likely account for only a fraction of the reduced CHD risk in the ASPREE population (N=13,131), with a range of other genetic and lifestyle factors contributing.

Strengths of the study include the sample size and unique ascertainment of the ASPREE population. The sequenced cohort was comprised of 13,131 individuals with an average age of 75 years, with no previous diagnosis of CHD or other cardiovascular events. It is rare for a population ascertained with these characteristics to be made available for genetic analysis. The sequenced cohort was the result of a unique set of circumstances made possible by the strict ASPREE inclusion criteria and age cut-off, and associated research biobank <sup>14,29</sup>.

Another strength of the study is that ASPREE participants were well characterised, each receiving a medical assessment by a general practitioner at enrolment, to confirm eligibility for the trial, and to rule out previous diagnoses of CHD <sup>14</sup>. This provided confidence that detected variant carriers were CHD event-free at enrolment. Other strengths of the study include the depth of sequencing, focus on canonical lipid metabolism genes with established biological effect, and stringency of variant curation used, to ensure only high-confidence variants were included in analyses.

Limitations of the study include our results not necessarily being generalizable to populations of non-European ancestry. Further, we caution the comparison of rare variant prevalence between ASPREE and reference populations such as gnomAD, due to the potential for technical artefacts introduced by differences in sequencing technologies and variant curation, and population stratification related to differences in genetic ancestry. These well-known sources of variability are compounded when attempting to compare rare variant frequencies between studies <sup>30</sup>. Nonetheless, our results suggest that rare *PSCK9/APOB* variants are enriched in healthy older

10

143 CHD-free individuals (Table 2), consistent with previous studies showing that LDL-C-lowering
 144 variants are associated with reduced risk for CHD and longevity <sup>1-9</sup>.

Regarding the genes analysed in our study, we focused on only the most established two 145 canonical lipid metabolism genes where rare loss-of-function variants have been demonstrated to 146 have a high effect in reducing LDL-C levels (PCSK9 and APOB)<sup>1,3,8,9</sup>. We did not examine 147 gain-of-function variants in the LDLR gene, or loss-of-function variants in other genes that have 148 been associated with LDL-C reduction (e.g. NPC1L1, LPA, APOC3, ANGPTL3/4, and ASGR1). 149 These additional genes were not included on the sequencing panel used. We also could not 150 calculate polygenic scores due to the targeted nature of the sequencing assay. 151 152 We did not functionally validate the detected rare variants, and we were unable to estimate the

degree to which each individual rare variant was associated with lower serum LDL-C levels. The relatively low number of rare variants detected necessitated combining rare variants together into a single group for blood lipid associations. A further limitation of our study was the lack of assessment of subclinical atherosclerosis in the ASPREE trial, including the absence of data on coronary artery calcium (CAC) and carotid intima-media thickness.

## 158 CONCLUSIONS

159 Cholesterol-lowering *PCSK9* and *APOB* variants are carried by healthy older CHD-free 160 individuals. Our study demonstrates the unique contribution of healthy elderly populations to 161 exploring genetic determinants of health and lifespan. Historically, healthy elderly populations 162 have not been the focus of large human genetic studies, mainly due to the difficulties in 163 ascertaining large numbers of samples in this age group. However, studies focused on the 164 healthy elderly represent an under-explored opportunity for detection of novel protective 165 variants, especially in the context of lipid regulation and CHD <sup>29</sup>. The ASPREE population, in

- 166 particular, provides an exceptional platform, with a unique age and CHD-free ascertainment
- 167 profile.

Acknowledgements: We thank the ASPREE trial staff in Australia and the United States, the ASPREE participants who volunteered for the trial, and the general practitioners and staff of the medical clinics who cared for the participants.

171 **Funding sources:** The ASPREE Healthy Ageing Biobank is supported by a Flagship cluster

- 172 grant (including the Commonwealth Scientific and Industrial Research Organisation, Monash
- 173 University, Menzies Research Institute, Australian National University, University of
- 174 Melbourne); and grants (U01AG029824) from the National Institute on Aging and the National
- 175 Cancer Institute at the National Institutes of Health, by grants (334047 and 1127060) from the
- 176 National Health and Medical Research Council of Australia, and by Monash University and the
- 177 Victorian Cancer Agency. P.L is supported by a National Heart Foundation Future Leader
- 178 Fellowship (102604).
- 179 Disclosures: Watts has received honoraria and/or research grants from Arrowhead, AstraZeneca,
- 180 Kowa, Regeneron, Sanofi, Amgen, and Novartis. Nicholls has received research support and/or
- 181 honoraria for Amgen, AstraZeneca, Eli Lilly, Esperion, Novartis, Merck, Pfizer, Iowa and
- 182 Sanofi-Regeneron. Sebra serves as Vice-President of Technology Development at Sema4.
- 183 Schadt serves as Chief Executive Officer at Sema4. No other conflicts were reported.
- **Ethics approval and patient consent statement:** Ethics approval for genetic analysis was
- obtained from the Alfred Hospital Human Research Ethics Committee. All participants provided
- 186 informed consent for genetic analysis.
- **Data availability statement:** Data are available from the corresponding author upon request.

#### 188 **References**

- 189 1. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and 190 protection against coronary heart disease. *N Engl J Med*. 2006;354(12):1264-1272.
- 1912.Dewey FE, Gusarova V, O'Dushlaine C, et al. Inactivating Variants in ANGPTL4 and Risk of192Coronary Artery Disease. N Engl J Med. 2016;374(12):1123-1133.
- 1933.Peloso GM, Nomura A, Khera AV, et al. Rare Protein-Truncating Variants in APOB, Lower Low-194Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circ Genom195Precis Med. 2019;12(5):e002376.
- 1964.Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and Risk of197Cardiovascular Disease and Diabetes. The New England journal of medicine. 2016;375(22):2144-1982153.
- 1995.Nomura A, Won HH, Khera AV, et al. Protein-Truncating Variants at the Cholesteryl Ester200Transfer Protein Gene and Risk for Coronary Heart Disease. Circ Res. 2017;121(1):81-88.
- 2016.Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and202LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019;321(4):364-373.
- 2037.Ye H, Zhao Q, Huang Y, et al. Meta-analysis of low density lipoprotein receptor (LDLR) rs2228671204polymorphism and coronary heart disease. *Biomed Res Int.* 2014;2014:564940.
- 2058.Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin206Biochem Rev. 2008;29(1):11-26.
- Rimbert A, Pichelin M, Lecointe S, et al. Identification of novel APOB mutations by targeted nextgeneration sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
   *Atherosclerosis.* 2016;250:52-56.
- 21010.Dron JS, Hegele RA. Complexity of mechanisms among human proprotein convertase subtilisin-211kexin type 9 variants. Curr Opin Lipidol. 2017;28(2):161-169.
- 21211.Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated213with exceptional longevity. JAMA. 2003;290(15):2030-2040.
- 21412.WeltyFK.Hypobetalipoproteinemiaandabetalipoproteinemia.CurrOpinLipidol.2152014;25(3):161-168.
- 21613.Graham I, Shear C, De Graeff P, et al. New strategies for the development of lipid-lowering217therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother. 2018;4(2):119-218127.
- McNeil JJ, Woods RL, Nelson MR, et al. Baseline Characteristics of Participants in the ASPREE
  (ASPirin in Reducing Events in the Elderly) Study. J Gerontol A Biol Sci Med Sci.
  2017;72(11):1586-1593.
- 22215.McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in223the Healthy Elderly. N Engl J Med. 2018;379(16):1509-1518.
- 22416.McNeil JJ, Woods RL, Nelson MR, et al. Effect of Aspirin on Disability-free Survival in the Healthy225Elderly. N Engl J Med. 2018;379(16):1499-1508.
- 22617.McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy227Elderly. N Engl J Med. 2018;379(16):1519-1528.
- 22818.Group AI. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized,229controlled trial. Contemporary clinical trials. 2013;36(2):555-564.
- 23019.Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-231dose aspirin for major adverse cardiovascular events in older people in Australia: results from232the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. *Med J Aust.* 2008;189(2):105-233109.
- 234 20. Lockery JE, Collyer TA, Abhayaratna WP, et al. Recruiting general practice patients for large
   235 clinical trials: lessons from the Aspirin in Reducing Events in the Elderly (ASPREE) study. *Med J* 236 *Aust.* 2019;210(4):168-173.

- 237 21. Lacaze P, Sebra R, Riaz M, et al. Familial Hypercholesterolemia in a Healthy Elderly Population.
   238 *Circ Genom Precis Med.* 2020.
- 239 22. Lacaze P, Sebra R, Riaz M, et al. Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals. *Genet Med.* 2020.
- 241 23. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706
  242 humans. *Nature*. 2016;536(7616):285-291.
- 24324.Elbitar S, Susan-Resiga D, Ghaleb Y, et al. New Sequencing technologies help revealing244unexpected mutations in Autosomal Dominant Hypercholesterolemia. Sci Rep. 2018;8(1):1943.
- 24525.Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density246lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and247meta-analyses. J Am Coll Cardiol. 2010;55(25):2833-2842.
- 26. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence
  variants: a joint consensus recommendation of the American College of Medical Genetics and
  Genomics and the Association for Molecular Pathology. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2015;17(5):405-424.
- 252 27. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL
  253 cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of
  254 individual data from 27 randomised trials. *Lancet.* 2012;380(9841):581-590.
- 255 28. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein
  256 cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian
  257 randomization analysis. *J Am Coll Cardiol.* 2012;60(25):2631-2639.
- 258 29. Lacaze P, Woods R, Zoungas S, et al. The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies. *Intern Med J.* 2017;47(4):461260 463.
- 26130.Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study designs and262statistical tests. Am J Hum Genet. 2014;95(1):5-23.

263

Table 1. Characteristics of Sequenced Participants at Enrolment. Sequenced participants
were enrolled in the ASPREE clinical trial, aged 70 years and older (average age 75 years),
without a previous diagnosis of cardiovascular disease, dementia, permanent physical disability,
or current diagnosis of life-threating cancer at enrolment. Most were white/Caucasian and 54%
were female.

	<b>ASPREE</b> <b>N=13,131</b> (mean age 75 years)
Female sex – no. (%)	7056 (54)
Age in years – no. (%)	
70-74 yr	7,894 (60)
75-79 yr	3,406 (26)
≥80 yr	1,831 (14)
<b>Race or ethnic group</b> <sup>a</sup> – no. (%)	
White/Caucasian	12,953 (99)
Other	178 (1)
Obese (BMI≥30 kg/m <sup>2</sup> ) <sup>b</sup> (%)	28
Current smoking (%)	4
Statin use <sup>c</sup> (%)	33
Heart, stroke or vascular disease <sup>d</sup> (%)	0

<sup>a</sup> Self-report.

<sup>b</sup> Obese was defined as body-mass index (weight in kilograms divided by the square of the

height in meters) of  $\geq 30$ .

<sup>c</sup> Anatomical Therapeutic Chemical (ATC) code C10 (lipid modifying agents).

<sup>d</sup> Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the

Elderly) Study 14

## Table 2: Prevalence of LDL cholesterol-lowering variants in a healthy elderly CHD-free

**population (ASPREE).** We sequenced N=13,131 individuals aged 70 years and older to detect cholesterol-lowering variants using two methods: 1) prediction of rare candidate loss-of-function, protein-truncating *PCSK9* and *APOB* variants; and 2) assessment of candidate variants identified in previously published functional or population studies. We also examined the effect of the common *PCSK9* R46L variant with lipid-lowering effect; rs11591147<sup>25</sup>. Variants were curated following ACMG/AMP Standards<sup>26</sup>.

Gene	Variant (GRCh37)	rsID	Туре	Consequence	ASPREE Carriers	ASPREE MAF N=13,131	gnomAD- NFE MAF N=64,603
RARE V	ARIANTS (MAF<0.01)						
PCSK9	NM_174936.3(PCSK9): c.709C>T (p.Arg237Trp)	rs148195424	SNV	Missense	44	0.00335	0.00093
PCSK9	NM_174936.3(PCSK9): c.1327G>A(p.Ala443Thr)	rs28362263	SNV	Missense	13	0.00099	0.00029
PCSK9	NM_174936.3(PCSK9): c.657+1G>T	rs142824171	SNV	Splice donor	7	0.00053	0.00007
PCSK9	NM_174936.3(PCSK9): c.1384T>C (p.Ser462Pro)	rs746115963	SNV	Missense	7	0.00053	0.00012
PCSK9	NM_174936.3(PCSK9): c.520C>T (p.Pro174Ser)	rs533273863	SNV	Missense	5	0.00038	0.00008
PCSK9	NM_174936.3(PCSK9): c.1863+1G>A	rs765335983	SNV	Splice donor	5	0.00038	0.00003
PCSK9	NM_174936.3(PCSK9): c.277C>T (p.Arg93Cys)	rs151193009	SNV	Missense	3	0.00023	0.00002
PCSK9	NM_174936.3(PCSK9): c.341T>C (p.Val114Ala)	rs775988212	SNV	Missense	2	0.00015	0.00003
PCSK9	NM_174936.3(PCSK9): c.471C>A (p.Asn157Lys)	rs143117125	SNV	Missense	2	0.00015	0.00005
PCSK9	NM_174936.3(PCSK9): c.1300C>T(p.Arg434Trp)	rs757143429	SNV	Missense	2	0.00015	0.00001
PCSK9	NM_174936.3(PCSK9): c.313C>T (p.Arg105Trp)	rs747072726	SNV	Missense	1	0.00008 *	0.00002
PCSK9	NM_174936.3(PCSK9): c.706G>A (p.Gly236Ser)	rs149489325	SNV	Missense	1	0.00008 *	0.00005
PCSK9	NM_174936.3(PCSK9): c.658-2A>C	rs371336612	SNV	Splice acceptor	1	0.00008 *	-
				TOTAL	92		
APOB	NM_000384.3(APOB): c.6253C>T(p.Arg2085Ter)	rs121918386	SNV	Stop gained	3	0.00023	0.00004
APOB	NM_000384.3(APOB): c.4503T>G (p.Tyr1501Ter)	rs368825685	SNV	Stop gained	1	0.00008 *	0.00001
APOB	NM_000384.3(APOB): c.1315C>T (p.Arg439Ter)	rs142066904	SNV	Stop gained	1	0.00008*	0.00003
APOB	NM_000384.2(APOB): c.11153C>G (Ser3718Ter)	-	SNV	Stop gained	1	0.00008 *□	-
APOB	NM_000384.2(APOB): c.7300C>T (p.Gln2434Ter)	-	SNV	Stop gained	1	0.00008 *□	-
APOB	NM_000384.3(APOB): c.6538C>T (p.Gln2180Ter)	rs1041962	SNV	Stop gained	1	0.00008 *□	-
APOB	NM_000384.2(APOB): c.2245-2A>G	-	SNV	Splice acceptor	1	0.00008 *□	-

APOB	NM_000384.2(APOB) 21228615CA>C (deletion)	-	INDEL	Frameshift	1	0.00008 *□	-
APOB	NM_000384.2(APOB) 21230841G>GT (insertion)	-	INDEL	Frameshift	1	0.00008 *□	-
				TOTAL	11		
PCSK9 F	R46L (MAF>0.01)						
PCSK9	NM_174936.3(PCSK9): c.137G>T (p.Arg46Leu)	rs11591147	SNV	Missense			
				HET	465	0.03541	0.01507
				НОМО	6	0.00046	0.0002

SNV = Single nucleotide variant, INDEL = Insertion/deletion, HET = Heterozygote, HOMO = Homozygote, pLoF = Predicted loss of function variant. MAF = Minor allele frequency.

\* Denotes a singleton variant detected in only one ASPREE participant/carrier <sup>[]</sup> Denotes a potentially novel protective *APOB* variant not previously described, or found in the gnomAD database <sup>30</sup>

Table 3. Variant carrier status in ASPREE is associated with reduced serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels. We compared serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels between variant carriers and N=9,540 non-carrier ASPREE controls. The multivariable linear regression model adjusted for age, gender, diabetes, hypertension, smoking status, alcohol use, and body mass index. We first tested association using raw unadjusted LDL-C and TC levels (not accounting for statin use), then separately using statin-adjusted levels (*adj*LDL-C, *adj*TC), dividing LDL-C and TC levels by 0.7 and 0.8 respectively for those using statin medication to estimate untreated levels, as done previously <sup>3</sup>. We identified statin users based on concomitant medications recorded by ASPREE at baseline. Data are presented as median (inter-quartile range). Statistical significance is denoted by P<0.001. To convert values from mg/dl to mmol/l multiply by 0.02586. ATC code C10 = Anatomical Therapeutic Chemical code C10 (lipid modifying agents).

Rare variant group <i>PCSK9/APOB</i> MAF<0.01	Non-Carriers N=9,540	Heterozygotes N=104	Homozygotes N=0	P- Value
LDL-C (mg/dl)	119.9 (96.7 to 143.1)	108.3 (81.2 to 131.5)	-	< 0.001
adjLDL-C (mg/dl)	131.5 (112.1 to 150.8)	112.1 (92.8 to 139.2)	-	<0.001
TC (mg/dl)	201.1 (177.9 to 228.2)	193.3 (170.1 to 220.4)	-	< 0.001
<i>adj</i> TC (mg/dl)	217.5 (193.4 to 241.6)	201.1 (177.9 to 225.7)	-	< 0.001
Common variant <i>PCSK9</i> rs11591147-T	Non-Carriers N=9,540	Heterozygotes N=465	Homozygotes N=6	P- Value
LDL-C (mg/dl)	119.9 (96.7 to 143.1)	112.1 (88.9 to 131.5)	106.35 (95.7 to 117.0)	< 0.001
adjLDL-C (mg/dl)	131.5 (112.1 to 150.8)	116.0 (96.7 to 135.3)	106.4 (95.7 to 117.0)	< 0.001
TC (mg/dl)	201.1 (177.9 to 228.2)	197.2 (170.1 to 216.6)	197.2 (168.2 to 211.7)	< 0.001
adjTC (mg/dl)	217.5 (193.4 to 241.6)	201.1 (183.6 to 227.1)	197.2 (168.2 to 211.7)	< 0.001

**Figure 1.** *PCSK9* and *APOB* rare variant carrier status in ASPREE is associated with reduced serum lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels. Shown is a comparison of LDL-C and TC levels at enrolment for carriers of rare variants (MAF<0.01) in *PCSK9* (N=93) and *APOB* (N=11), compared with non-carrier controls (N=9,540) from ASPREE. Results indicate that rare *APOB/PCSK9* rare variant carrier status is associated with reduced serum LDL-C and TC levels. Linear regression was used to compare statistical differences between groups adjusting for covariates. We first tested association using raw unadjusted LDL-C (**a**) and TC (**b**) levels (not adjusting for statin use), then separately using statin-adjusted *adj*LDL-C (**c**) and *adj*TC (**d**), dividing LDL-C and TC levels by 0.7 and 0.8 respectively for participants using statin medication to estimate untreated levels <sup>3</sup>. Median values are shown as coloured solid lines (magenta and red). We identified statin users based on concomitant medications recorded by ASPREE at baseline. Statistical significance is denoted as \*\*\* P=<0.001. Dyslipidaemia (dotted lines) is defined as serum LDL-C higher than 160 mg/dl, or serum TC higher than 212 mg/dl <sup>14</sup>. To convert values from mg/dl to mmol/l multiply by 0.02586.

